This is a working overview of responder analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
"The Federal Power Commission, Job Bias, and NAACP v. FPC." Akron Law Review, vol. 10, no. 556 (January 1, 1977). "Assumption of the Risk, Comparative Fault and Strict Liability After Rozell." (47 Louisiana Law Review, vol. 57, no. 791 (January 1, 1987). "A Primer on the Louisiana Products Liability Act." Louisiana Law Review, vol. 49, no. 565 (January 1, 1989). The Dimension of Time in the Louisiana Products Liability Act (42 Louisiana Bar Journal (January 1, 1994) "Role of the Consumer Expectation Test Under Louisiana's Products Liability Tort Doctrine." Tulane Law Review, vol. 69, no. 1 (1994-1995), pp. 117–164. Louisiana State Constitutional Law. LSU Publications Institute (January 1, 2012) Kennedy, John (October 7, 2025). How to Test Negative for Stupid: And Why Washington Never Will. Broadside Books. ISBN 978-0063428164.
At this time, the Selous Scouts comprised about 120 personnel and all of its officers were white. Black soldiers were offered bonuses that almost doubled their salary if they agreed to serve with the Selous Scouts. The unit was named after the British explorer Frederick Selous (1851–1917) and its motto was pamwe chete—a Shona phrase meaning "all together", "together only" or "forward together". The charter of the Selous Scouts directed them to "the clandestine elimination of terrorism both within and without the country". The name Selous Scouts had previously been attached to the Rhodesian Armoured Car Regiment of the Federal Army of Rhodesia and Nyasaland. The South African Police's Special Branch provided funding for the Selous Scouts. This formed part of the South African Government's extensive support for the Rhodesian counterinsurgency effort. Many South African Defence Force personnel served in the Selous Scouts between 1973 and 1979, including during operations in Rhodesia, Mozambique and Zambia. After the South African Government publicly withdrew the South African Police units which had been deployed to Rhodesia in 1975 SADF personnel continued to serve with the Selous Scouts. A witness who testified at the post-Apartheid South African Truth and Reconciliation Commission stated that the Selous Scouts were covertly funded by the South African Police and South African police officers also served in the unit.
Brown bread, in contrast to white bread, is bread made with significant amounts of whole grain flours, usually wheat sometimes with corn and or rye flours. In some countries brown breads often get their characteristic dark color from ingredients such as molasses or coffee. In Canada, the UK, Ireland and South Africa, it is a blend of white flour and whole wheat flour. Wholemeal bread within the UK must be made solely from whole wheat flour. In New England and the Maritimes, brown bread is bread sweetened with molasses.
Sources: en.wikipedia.org
== Further reading == Reineccius, Gary (1998). Sourcebook of Flavors. Berlin: Springer. ISBN 978-0-8342-1307-4. Fennema, O.R., ed. (1985). Food Chemistry (2nd ed.). New York: Marcell Dekker, Inc. pp. 46–50. Bell, L.N.; Labuza, T.P. (2000). Practical Aspects of Moisture Sorption Isotherm Measurement and Use (2nd ed.). Egan, MN: AACC Egan Press.
In 1890, Colonel Lilly fully turned over the day-to-day management of the business to J. K., who ran the company for 34 years. The 1890s were a tumultuous decade economically, but the company flourished. In 1894, Lilly purchased a manufacturing plant to be used solely for creating capsules. The company also made several technological advances in the manufacturing process, including automating its capsule production. Over the next few years the company annually created tens of millions of capsules and pills. In 1898, Lilly's son, J. K. Lilly, inherited the company and became its president following Colonel Lilly's death. At the time of Colonel Lilly's death, the company had a product line of 2,005 items and annual sales of more than $300,000. Colonel Lilly was a pioneer in the modern pharmaceutical industry, with many of his early innovations later becoming standard practice. His ethical reforms in a trade that was marked by outlandish claims of miracle medicines began a period of rapid advancement in the development of medicinal drugs. J. K. Lilly continued to advocate for federal regulation on medicines. As the Lilly company grew, other businesses set up operations near the plant on Indianapolis's near south side. The area developed into one of the city's major business and industrial hubs. Lilly's production, manufacturing, research, and administrative operations in Indianapolis eventually occupied a complex of more than two dozen buildings, which covered 15-block area, in addition to its production plants along Kentucky Avenue.
=== Phase 3 === AB-103 – topical – alopecia – minoxidil sulfotransferase stimulant (adjunct to minoxidil) Clascoterone (Breezula, Winlevi; CB-03-01) – topical – alopecia – androgen receptor antagonist Diphencyprone (diphenylcyclopropenone, samcyprone) – topical – alopecia areata – immunomodulator Dutasteride (AD-208) – oral – alopecia – 5α-reductase inhibitor Minoxidil oral extended-release (VDPHL01, VDPHL-01, VDPHL) – oral – alopecia, male pattern baldness – potassium channel opener (prodrug of minoxidil sulfate) Minoxidil sublingual (SLM) – sublingual – alopecia – potassium channel opener (prodrug of minoxidil sulfate) Pyrilutamide (EX-A5504, HY-145451, KX 826) – topical – alopecia – androgen receptor antagonist Upadacitinib (Rinvoq; ABT-494) – oral – alopecia areata – Janus kinase 1 inhibitor
=== Cost === In a 2020 cost-effectiveness study dupilumab was inferior to endoscopic sinus surgery (ESS): At a 36-year time horizon dupilumab treatment cost $536,420.22 and produced 8.95 QALYs (quality-adjusted life years), while ESS cost roughly one tenth at $50,436.99 and produced 9.80 QALYs.
Sources: en.wikipedia.org
Mkhedrioni relied on illegal sources of income (targeting gasoline supplies) and exploited connections with Moscow's Georgian underworld. Mkhedrioni members were often accused of criminal activity, extorting "protection money" from businesses in areas which they effectively controlled, operating roadblocks where drivers would be "fined", smuggling drugs and committing robberies. By 1991, the Mkhedrioni was claimed to have had about 1,000 fighters and 10,000 associate members – considerably more than the official state National Guard. Despite Gamsakhurdia and Ioseliani sharing a broadly similar nationalist outlook, the two men fell out badly shortly after Gamsakhurdia came to power in November 1990. In February 1991, Ioseliani was imprisoned without trial, along with many of his supporters, and the Mkhedrioni was banned. In August 1991, just after the Soviet coup attempt, Gamsakhurdia sacked Tengiz Kitovani, the commander of Georgia's National Guard, and his Prime Minister Tengiz Sigua resigned around the same time. Kitovani soon formed an anti-Gamsakhurdia alliance with Sigua and the imprisoned Ioseliani. In December 1991, Kitovani's supporters released Ioseliani from jail and launched a violent coup d'état against the Gamsakhurdia government in alliance with the Mkhedrioni. Intense gun battles took place in the streets of Tbilisi between the rebels and "Zviadists" holed up in the state parliament building during December 1991 – January 1992, which ended with Gamsakhurdia fleeing to the breakaway Russian republic of Chechnya. At least 100 people were killed in the fighting.
There are two more enzymes that catalyze the conversion of versicolorin A to demethylsterigmatocystin: AflN, an oxidase and AflM, a reductase. These enzymes use both molecular oxygen and two NADPH's to dehydrate one of the hydroxyl groups on the anthraquinone and open the quinine with the molecular oxygen. Upon forming the aldehyde in the ring opening step, it is oxidized to form the carboxylic acid and subsequently a decarboxylation event occurs to close the ring, forming the six-member ether ring system seen in demethylsterigmatocystin. The next two steps in the biosynthetic pathway is the methylation by S-adenosyl methionine (SAM) of the two hydroxyl groups on the xanthone part of demethysterigmatocystin by two different methyltransferases, OmtB and OmtA. This yields O-methylsterigmatocystin. In the final steps there is an oxidative cleavage of the aromatic ring and loss of one carbon in O-methylsterigmatocystin, which is catalyzed by OrdA, an oxidoreductase. Then a final recyclization occurs to form aflatoxin B1.
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC). To a lesser extent, it is used at high doses for locally advanced prostate cancer (LAPC) as a monotherapy without castration. Bicalutamide was also previously used as monotherapy to treat localized prostate cancer (LPC), but authorization for this use was withdrawn following unfavorable trial findings. Besides prostate cancer, bicalutamide is limitedly used in the treatment of excessive hair growth and scalp hair loss in women, as a puberty blocker and component of feminizing hormone therapy for transgender girls and women, to treat gonadotropin-independent early puberty in boys, and to prevent overly long-lasting erections in men. It is taken by mouth. Common side effects of bicalutamide in men include breast growth, breast tenderness, and hot flashes. Other side effects in men include feminization and sexual dysfunction. Some side effects like breast changes and feminization are minimal when combined with castration. While the medication appears to produce few side effects in women, its use in women is not explicitly approved by the Food and Drug Administration (FDA) at this time. Use during pregnancy may harm the baby. In men with early prostate cancer, bicalutamide monotherapy has been found to increase the likelihood of death from causes other than prostate cancer.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.